* Genentech Inc. of South San Francisco said U.S. regulators delayed action on the company’s application to market breast cancer drug Herceptin for a wider group of women to review additional information. The Food and Drug Administration extended the review period for the application 90 days beyond the Aug. 17 due date.
* Alaska’s legislature approved a 22.5% tax on energy producer profits to help the state get a proposed $20-billion natural gas pipeline built. Alaska’s natural gas, discovered decades ago, is not being tapped today because there is no way for it to reach customers in the Lower 48 states.
* Supplement and vitamin retailer GNC Corp. of Pittsburgh has withdrawn a $400-million initial public offering because of unfavorable market conditions, including the alleged terror plot discovered this week, a spokesman said.